SCHEMBL5268682

SCHEMBL5268682

Cc1nccc2c1[nH]c1ccc(Cl)cc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 8/20 0.61
TDO2 P48775 3/20 0.61
KDM4E B2RXH2 2/20 0.61
ALDH1A1 P00352 2/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2D6 P10635 2/20 0.61
HPGD P15428 2/20 0.61
HSD17B10 Q99714 2/20 0.61
MEN1 O00255 1/20 0.61
GABRP O00591 1/20 0.61
GABRD O14764 1/20 0.61
MAPT P10636 1/20 0.61
GABRA1 P14867 1/20 0.61
TSHR P16473 1/20 0.61
GABRB1 P18505 1/20 0.61
GABRG2 P18507 1/20 0.61
NFKB1 P19838 1/20 0.61
APEX1 P27695 1/20 0.61
GABRB3 P28472 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29756356 0.98 MAOA (0.59) MAOATDO2KDM4EALDH1A1CYP1A2
Hydrochloric Acid SCHEMBL21326137 0.98 MAOA (0.59) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL6123343 0.89 MAOA (0.56) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL16126068 0.87 CCNB2 (0.68) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL6123249 0.84 TDO2 (0.57) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL6122431 0.84 MAOA (0.54) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL29756369 0.81 CHUK (0.49) TDO2KDM4EALDH1A1HPGDMEN1
SCHEMBL6456554 0.81 MAOA (0.61) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL29227284 0.81 MAOA (0.61) MAOATDO2KDM4EALDH1A1CYP1A2
SCHEMBL2720910 0.81 MAOA (0.61) MAOATDO2KDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3792262-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2026-04-15 EP disclosed
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2025-10-30 US disclosed
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2025-04-15 US disclosed
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2024-06-06 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
CN-110382496-B Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders 赛诺菲 2022-08-09 CN disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2020-03-26 US disclosed
EP-3535263-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS Sanofi (FR) 2019-09-11 EP disclosed
WO-2007051630-A1 HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIFOULING AGENTS Eidgenössische Technische Hochschule Zürich (CH) 2007-05-10 WO disclosed
EP-1783128-A1 Heterocyclic compounds and their use as antifouling agents Eidgenössische Technische Hochschule Zürich (CH) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885TDO2 89/4885KDM4E 706/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885TDO2 89/4885KDM4E 706/4885
US-20200095242-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 MAOA 245/4885TDO2 89/4885KDM4E 706/4885
US-20240182469-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 MAOA 245/4885TDO2 89/4885KDM4E 706/4885
US-12275733-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 MAOA 245/4885TDO2 89/4885KDM4E 706/4885
US-20250333412-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS COL2A1, IDO1, COL1A1 MAOA 246/4885TDO2 82/4885KDM4E 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.